Get the Stockscreener App
7.48
2.33%
0.17
After Hours:
7.51
0.03
+0.40%
Bicycle Therapeutics Plc Adr stock is traded at $7.48, with a volume of 238.83K.
It is up +2.33% in the last 24 hours and down -9.00% over the past month.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
See More
Previous Close:
$7.31
Open:
$7.27
24h Volume:
238.83K
Relative Volume:
0.77
Market Cap:
$373.48M
Revenue:
$36.90M
Net Income/Loss:
$-166.28M
P/E Ratio:
-2.2736
EPS:
-3.29
Net Cash Flow:
$-203.53M
1W Performance:
+18.35%
1M Performance:
-9.00%
6M Performance:
-8.78%
1Y Performance:
-63.24%
1-Day Range:
$7.27
$7.83
1-Week Range:
$6.30
$7.83
52-Week Range:
$6.03
$21.50
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Name
Bicycle Therapeutics Plc Adr
Sector
Industry
Phone
011441223261503
Address
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
7.48 | 507.08M | 36.90M | -166.28M | -203.53M | -3.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Hold |
| Oct-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-08-24 | Initiated | Stephens | Equal-Weight |
| Sep-06-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-11-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Aug-31-22 | Initiated | Cowen | Outperform |
| Jul-28-22 | Initiated | Barclays | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Apr-13-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Apr-07-22 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-14-22 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | SVB Leerink | Outperform |
| Dec-09-21 | Initiated | Needham | Buy |
| Sep-30-21 | Initiated | B. Riley Securities | Buy |
| Apr-20-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-12-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-20 | Initiated | Oppenheimer | Outperform |
| Apr-17-20 | Initiated | H.C. Wainwright | Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Sep-11-19 | Upgrade | Goldman | Neutral → Buy |
| Jun-17-19 | Initiated | Canaccord Genuity | Buy |
| Jun-17-19 | Initiated | Goldman | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
| Jun-17-19 | Initiated | Piper Jaffray | Overweight |
View All
Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Coverage Initiated by Analysts at Truist Financial - Defense World
Preferred dividends of Bicycle Therapeutics Plc Sponsored ADR – HAM:50BA - TradingView
Truist Securities initiates coverage on Bicycle Therapeutics stock with Hold rating - Investing.com UK
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - PR Newswire
Acadian Asset Management LLC Buys 572,439 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
A new trading data show Bicycle Therapeutics Plc ADR (BCYC) is showing positive returns. - setenews.com
Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 8.8% Following Analyst Downgrade - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Down 8.8% After Analyst Downgrade - Defense World
Pinnacle Associates Ltd. Sells 42,325 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Analysts Set Expectations for BCYC Q1 Earnings - MarketBeat
EBITDA per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap DownHere's Why - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.8% on Earnings Beat - MarketBeat
Bicycle Therapeutics stock price target raised to $12 from $10 at Citizens By Investing.com - Investing.com South Africa
RBC Capital downgrades Bicycle Therapeutics stock on delayed pipeline progress By Investing.com - Investing.com South Africa
Bicycle Therapeutics earnings beat by $0.23, revenue topped estimates - Investing.com South Africa
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results - Placera.se
Bicycle Therapeutics PLC Sponsored ADR $BCYC Position Boosted by Tybourne Capital Management HK Ltd. - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 5.2%Here's Why - MarketBeat
100,291 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Janney Montgomery Scott LLC - Defense World
Global X MLP & Energy Infrastructure ETF $MLPX Holdings Boosted by Janney Montgomery Scott LLC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Receives “Sell (D-)” Rating from Weiss Ratings - Defense World
Financial Comparison: IRIDEX (NASDAQ:IRIX) and Micro Imaging Technology (OTCMKTS:MMTC) - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analyzing Fractyl Health (NASDAQ:GUTS) & Plus Therapeutics (NASDAQ:PSTV) - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 10.5%What's Next? - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 3,231 Shares - MarketBeat
Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 2,263 Shares of Stock - MarketBeat
Maze Therapeutics appoints Hervé Hoppenot as chairman of the board - Investing.com
Bicycle Therapeutics Sees Unusually Large Options Volume (NASDAQ:BCYC) - Defense World
Stock Traders Purchase High Volume of Bicycle Therapeutics Call Options (NASDAQ:BCYC) - MarketBeat
Goldman Sachs Group Inc. Takes Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 7.8%Here's Why - MarketBeat
126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Acadian Asset Management LLC - MarketBeat
Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $22.22 - MarketBeat
126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Bought by Acadian Asset Management LLC - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
3 Stocks To Buy Under $10 That Could Triple From Here - Barchart.com
Cubist Systematic Strategies LLC Sells 2,650 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
Bicycle Therapeutics appoints oncology veterans Dansey and Hoppenot to board - Investing.com India
Caption Management LLC Sells 81,517 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Armistice Capital LLC Has $22.69 Million Holdings in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Long Focus Capital Management LLC Acquires 750,661 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR $BCYC Stock Holdings Cut by Tybourne Capital Management HK Ltd. - MarketBeat
Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025 - GlobeNewswire Inc.
Candriam S.C.A. Acquires 117,331 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Analysts’ Weekly Ratings Updates for Bicycle Therapeutics (BCYC) - Defense World
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com
Bicycle Therapeutics Plc Adr Stock (BCYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):